BMS Archive

Fungi · Scientific monograph

Phellinus linteus

Sanghuang / Meshimakobu

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Immunological Research, Cellular & Immune Studies, Inflammatory Pathways

Research overview

Historical use

One of the most prized medicinal mushrooms in East Asian medicine, known as 'Sang Huang' (yellow mulberry) in China and 'Meshimakobu' in Japan. Used for over 2,000 years primarily as an anti-tumour agent, also for haemostasis, dysentery, and as an immune tonic. Grows on mulberry trees (Morus species) and was historically one of the most expensive medicinal fungi.

Modern research context

Strongly investigated for anti-tumour and immunomodulatory properties [5]. Preclinical studies show consistent anti-proliferative effects across multiple cancer cell lines (breast, prostate, colon, leukaemia) [5]. Three CONSORT-compliant randomised controlled trials have documented immune enhancement effects of oral Phellinus linteus extract in healthy subjects [1][2][3]. Perioperative use as a nutraceutical adjunct in pancreatic cancer management has been clinically evaluated [4]. Anti-inflammatory properties relevant to IBD and arthritis are documented in preclinical models [5].

Adverse effects

Limited human clinical data. Mild GI symptoms reported. No significant adverse effects documented at typical research doses.

Contraindications

Anticoagulants — additive antiplatelet effect. Immunosuppressants — pharmacodynamic antagonism. Insufficient data for definitive contraindication profile.

Clinical and phytochemical data

Used part

Fruiting body and mycelium

Primary active compounds

  • Hispidin (styrylpyrone compound)

  • Polysaccharides (PL-1, PL-2 — beta-glucans)

  • Protocatechuic acid

  • Caffeic acid

  • Inoscavin A

  • Davallialactone

Mechanism of action

Hispidin and related styrylpyrones inhibit PKC (protein kinase C) and scavenge free radicals. Polysaccharides activate macrophages and NK cells via Dectin-1/TLR-4; upregulate IL-12 and IFN-γ. Anti-tumour activity involves TRAIL-mediated apoptosis and VEGF inhibition (anti-angiogenic). Antidiabetic effect via α-glucosidase inhibition and improved insulin sensitivity through PPAR-γ.

Pharmacokinetics

Absorption

Absorption data is compound-dependent. Protocatechuic acid (PCA), a phenolic acid found in Phellinus linteus, is absorbed after oral dosing in humans; plasma concentrations were quantified following single and multiple oral doses in 12 healthy subjects [1]. No human absorption data exist for hispidin or the major beta-glucan fractions — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Limited human PK data. Hispidin has demonstrated absorption in animal models; polysaccharide fractions show limited systemic absorption.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Hispidin and styrylpyrone compounds are lipophilic and distribute widely to liver, adipose tissue, and inflammatory foci. Polysaccharide fractions preferentially target GALT, spleen, and bone marrow. No formal human tissue distribution data available; preclinical rodent data only.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Hepatic phase I/II metabolism of phenolic compounds assumed. Polysaccharides fermented by gut microbiota.

Excretion

Urinary excretion of protocatechuic acid was measured in healthy human subjects following oral dosing, enabling calculation of renal clearance [1]. No human excretion data are available for hispidin, polysaccharides, or other major Phellinus linteus constituents — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Renal excretion of phenolic metabolites; fecal for unabsorbed polysaccharides.

Safety and interactions

Drug interactions

Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.

Toxicity

LD50 >5 g/kg (oral, mice) for polysaccharide extract. No significant organ toxicity in 90-day subacute animal studies. Human safety data very limited.

Special precautions

Pregnancy

Insufficient human clinical data. Avoid during pregnancy.

Lactation

No data on breast milk excretion. Avoid during breastfeeding.

Hepatic impairment

No hepatotoxicity documented. Limited data; standard monitoring recommended.

Renal impairment

No specific risk identified. No dose adjustment data available.

Sources and references

  1. [1] - Ku YH., "Efficacy of Phellinus linteus extract on immunity enhancement: A CONSORT-randomized, double-blind, parallel-group study.", Medicine (Baltimore), 2022, PMID: 36221338
  2. [2] - Ku YH., "Effects of Phellinus linteus extract on immunity improvement: A CONSORT-randomized, double-blind, parallel-group study.", Medicine (Baltimore), 2022, PMID: 36042633
  3. [3] - Ku YH., "Clinical trial to analyze the effects of oral intake of Phellinus linteus (sanghuang) extract on immune function.", Trials, 2021, PMID: 34838112
  4. [4] - Kim J., "Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Pancreatic Cancer Patients.", Integr Cancer Ther, 2025, PMID: 40590265
  5. [5] - Chen H., "Traditional uses, fermentation, phytochemistry and pharmacology of Phellinus linteus: A review.", Fitoterapia, 2016, PMID: 27343366

Additional source links

Continue browsing